Project Grant R01HL175937
Award Date
9/17/24
Completion Date
6/30/28
Dollars Obligated
$1.6M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, in the amount of $786,139.00 with a project period from Sep 15, 2024 to Jun 30, 2029. The grant funds the development of a technique to dynamically image the lung using hyperpolarized 129Xe MRI during free-breathing, which will enable...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,160,157 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Liberandum Technologies, Inc. in San Francisco, CA. The goal of this Phase I Small Business Innovation Research (SBIR) project is to develop and test a bidirectional synchronous flow-controlled ventilation system to improve oxygenation and ventilation in patients with acute respiratory distress syndrome (ARDS). The ventilation system aims to provide gentle...
This federal Project Grant award, valued at $156,665.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania. The award supports a research project titled "Mesenchymal Cell Plasticity and Signaling in Lung Regeneration", which aims to examine how specific mesenchymal cell lineages contribute to adaptive versus maladaptive lung regeneration after severe...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $742,810 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Virginia (UVA) to develop diagnostic and monitoring tools using hyperpolarized gas magnetic resonance imaging (HGMRI) to detect and manage acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, determine HGMRI responses before and after rejection...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,063,324 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Tulane University. The grant, awarded on June 5, 2025, will support research to investigate the metabolic requirements and survival mechanisms of lung and nasal tissue-resident memory CD4+ T cells, and their interactions with lung fibroblasts, to enhance the understanding of pulmonary host defenses against respiratory pathogens. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $740,317 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Washington University in St. Louis to conduct research on the regulation of primary and secondary alveologenesis by FGF signaling pathways. The research aims to identify novel transcriptional mechanisms that regulate myofibroblast function during primary alveologenesis, as well as the cellular mechanisms by which FGF signaling regulates septal...
This Project Grant award, valued at $605,678.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The study, conducted by the University of South Alabama, aims to explore the concept that a "base oxidation and repair activated chromatin restructuring" (BRACR)...
This $683,564 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand how aberrant signaling in alveolar epithelial cells contributes to the development of pulmonary fibrosis. The award to The Trustees of the University of Pennsylvania will fund studies using complementary in vivo mouse models and an induced pluripotent stem cell-based human alveolar type 2 cell model to investigate how the integrated...
The University of Pennsylvania received a $798,727 Cooperative Agreement grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The project, titled "The Penn LungMAP 3 Team: Defining Chronic Lung Disease", aims to expand the understanding of the human lung in respiratory diseases, with a focus on cataloging the phenotypes of adult lung diseases like COPD and rare diseases, identifying molecular defects in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Texas Health Science Center at Houston (UTHealth). The 7-year grant, effective March 1, 2025 through December 31, 2031, supports UTHealth's "Hypoxia-Inflammation Program" focused on understanding and therapeutically targeting hypoxia-inducible factors (HIFs) to address heart and lung diseases. The program consists...